Amplifying Curcumin's Antitumor Potential: A Heat-Driven Approach for Colorectal Cancer Treatment

Area of Science:

• Oncology
• Cancer Research
• Pharmacology

Background:

• Peritoneal metastases from colorectal cancer (CRC) have a poor prognosis and are often resistant to chemotherapy.
• Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for select CRC patients.
• Curcumin, a natural compound, shows potential for HIPEC due to lower toxicity and direct peritoneal delivery.

Purpose of the Study:

• To investigate the efficacy of curcumin in HIPEC conditions.
• To compare curcumin's efficacy with mitomycin-C under hyperthermia.
• To explore the impact of genetic mutations on treatment response.

Main Methods:

• Developed an in vitro hyperthermic model simulating clinical HIPEC.
• Treated three CRC cell lines (SK-CO-1, COLO205, SNU-C1) with curcumin or mitomycin-C.
• Assessed cell viability and proliferation under normothermic and hyperthermic conditions.

Main Results:

• Hyperthermia significantly enhanced curcumin's antitumor efficacy, reducing cell viability by half compared to normothermia.
• Curcumin showed efficacy in p53-mutated cells where mitomycin-C did not.
• Observed mutation-specific differences in treatment response.

Conclusions:

• Hyperthermia augments curcumin's antitumor effects in vitro.
• Curcumin may be a more effective HIPEC agent than mitomycin-C, with potential for specific CRC subtypes.
• Curcumin-based HIPEC could offer a novel, less toxic therapeutic strategy for peritoneal metastases.